Are drug-eluting stents safe in the long term?

Généreux, Philippe; Mehran, Roxana
January 2009
CMAJ: Canadian Medical Association Journal;1/20/2009, Vol. 180 Issue 2, p154
Academic Journal
The article presents the author's views on the long-term safeness of the use of drug-eluting stents. It mentions that several concerns have been raised regarding the safety of the said drugs. A study was done to evaluate the long-term rates of death and myocardial infarction associated with the use of the drug-eluting stents as compared with the bare-metal stents. Results revealed that compared with the bare-metal stents, drug-eluting stents are associated with a lower mortality and a lower combined of death or repeat revascularization. It also explores the temporal change in outcomes of the study.


Related Articles

  • Mechanical reperfusion therapy for acute myocardial infarction: Stent PAMI, ADMIRAL, CADILLAC and beyond. Brodie, B. R.; Stuckey, T. D. // Heart;Mar2002, Vol. 87 Issue 3, p191 

    Mechanical reperfusion has gained increasing acceptance as a reperfusion strategy for acute myocardial infarction as a result of data from numerous randomised trials showing superior outcomes. Recently, the stent PAMI, ADMIRAL, and CADILLAC trials have documented further improvement in outcomes...

  • Comparison of an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients With Coronary Artery Disease. Stone, Gregg W.; Midei, Mark; Newman, William; Sanz, Mark; Hermiller, James B.; Williams, Jerome; Farhat, Naim; Mahaffey, Kenneth W.; Cutlip, Donald E.; Fitzgerald, Peter J.; Sood, Poornima; Xiaolu Su; Lansky, Alexandra J. // JAMA: Journal of the American Medical Association;4/23/2008, Vol. 299 Issue 16, p1903 

    The article presents a study comparing the angiographic outcomes in coronary artery disease patients using everolimus-eluting verses those using paclitaxel-eluting stents. The objectives, design and setting of the controlled patient trial are defined. Research showed that the everolimus stent...

  • Novel bioabsorbable stents are a pace apart. Pinn, Stephen // British Journal of Hospital Medicine (17508460);Apr2008, Vol. 69 Issue 4, p189 

    The article presents a study of a novel bioabsorbable drug-eluting stent for patients with single de-novo coronary artery lesions. The rate of major adverse cardiac events was 3.3%, with only one patient having a non-Q-wave myocardial infarction and no target lesion revascularization at year...

  • Initial culprit-only versus initial multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: results from the Ibaraki Cardiovascular Assessment Study registry. Abe, Daisuke; Sato, Akira; Hoshi, Tomoya; Takeyasu, Noriyuki; Misaki, Masako; Hayashi, Mayu; Aonuma, Kazutaka // Heart & Vessels;Mar2014, Vol. 29 Issue 2, p171 

    We investigated clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) treated for initial culprit-only or by initial simultaneous treatment of nonculprit lesion with culprit lesion. Optimal management of multivessel...

  • PCI in Addition to Medical Therapy for Stable CAD -- The Debate Continues. Boyle, Andrew J. // Clinical Cardiology Alert;Jun2012, Vol. 31 Issue 6, p43 

    The author discusses a study, by EL Hannan and colleagues, which revealed that most patients in New York State Cardiac Diagnostic Catheterization Database with stable coronary artery disease (CAD) undergoing diagnostic catheterization received percutaneous coronary intervention (PCI) and had...

  • Comparing outcomes from bare metal and drug-eluting coronary stents.  // British Journal of Hospital Medicine (17508460);Jul2008, Vol. 69 Issue 7, p421 

    The article presents a study which assesses the efficacy of drug-eluting stents on the risk of thrombosis on Medicare beneficiaries. The patients have received drug-eluting and bare metal stent between September and December 2003. The study reveals that the stents reduce the need for repeat...

  • 2016 - PCI with drug-eluting stents reduced revascularizations, but not mortality or MI, compared with bare-metal stents. Hudson, Michael // ACP Journal Club;11/15/2016, Vol. 165 Issue 10, p1 

    Question In patients with coronary artery disease (CAD) who are having percutaneous coronary intervention (PCI), what are the relative efficacies and harms of newer-generation drug-eluting stents (DESs) and bare-metal stents (BMSs)? Methods Design Randomized controlled trial (RCT) (Norwegian...

  • Vascular Stenting vs. Bypass for Multivessel Disease. Zepf, Bill // American Family Physician;11/1/2001, Vol. 64 Issue 9, p1613 

    Presents information on a study by P.W. Serruys and others on the issue of endovascular versus open-heart surgery for treatment of multivessel coronary artery disease. Description of the study and its results; Conclusion that stenting is less expensive than bypass grafting and not associated...

  • What reimbursement for coronary revascularization with drug-eluting stents? Tarricone, Rosanna; Marchetti, Monia; Lamotte, Mark; Annemans, Lieven; de Jong, Peter // European Journal of Health Economics;Dec2004, Vol. 5 Issue 4, p309 

    We investigated the clinical and economic impact of sirolimus-eluting coronary stents (SES) at a nationwide level as to advice about the feasible reimbursement policy for the Italian Health Care System (SSN). A decision model compared bare metal stents (BMS) and SES in terms of costs and repeat...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics